Evidence Trace, complete trial record

In plain terms

In plain terms: Carnosine shows early signals in human research but the evidence is limited -- small trials, surrogate endpoints, or not yet independently replicated. It is an emerging area, not yet a proven one.

Carnosine

C Limited: small, mixed or unreplicated trials

Category Supplements

Evidence RCT (limited)

Reviewed July 2026

PMIDs 39770949 · 29420997 · 38172006 · 31987255 · 38004228 · 39599686 · 42308284 · 34333586 · 40999397

The endpoint this grade is based on: Surrogate biomarker endpoint, Glycemic markers in adults with prediabetes or type 2 diabetes, on small mixed trials; musculoskeletal measures were tested and were null. Nothing tests healthy adults, and most of the wider literature is on the precursor beta-alanine, a different agent.

The evidence as the record states it

Evidence record

PMID 39770949 PMID 29420997 PMID 38172006 PMID 31987255 PMID 38004228 PMID 39599686 PMID 42308284 PMID 34333586 PMID 40999397

All trials cited enrolled adults with prediabetes, type 2 diabetes or overweight; nothing tests healthy adults. Glycemic markers: Houjeghani et al. (Nutr Res, 2018; PMID 29420997), Hariharan et al. (Nutr Metab Cardiovasc Dis, 2024; PMID 38172006) and the Peng et al. meta-analysis (Complement Ther Med, 2020; PMID 31987255) are positive on HbA1c or glucose-tolerance glucose with high heterogeneity and no effect on fasting glucose, HOMA-IR or lipids in the pooled data. Null from the same parent trial as Hariharan: Saadati et al. (Nutrients, 2024; PMID 39770949), no effect on grip strength, lean mass, fat, visceral fat or bone; Saadati et al. (Nutrients, 2023; PMID 38004228), no effect on blood pressure, endothelial function, arterial stiffness, lipids, liver or kidney outcomes; Saadati et al. (Nutrients, 2024; PMID 39599686), no effect on inflammatory markers or adipokines. O'Toole et al. (J Int Soc Sports Nutr, 2026; PMID 42308284): 299 adults, no overall effect on grip strength or performance. Pooled analyses that mix carnosine with its precursor beta-alanine, Matthews et al. (Adv Nutr, 2021; PMID 34333586) and Li et al. (BMC Endocr Disord, 2025; PMID 40999397), are labeled as such and do not grade carnosine alone. Grade C rests on the glycemic use; the musculoskeletal use is D, Route 2.

PMID 39770949 PMID 29420997 PMID 38172006 PMID 31987255 PMID 38004228 PMID 39599686 PMID 42308284 PMID 34333586 PMID 40999397

Evidence by specific use

Glycemic markers in prediabetes or type 2 diabetes

Grade C

Houjeghani et al. (Nutr Res, 2018; PMID 29420997): 54 adults with type 2 diabetes, 1 g/day for 12 weeks, fasting glucose 13 mg/dL and HbA1c 0.6 points lower than placebo, fat mass lower. Hariharan et al. (Nutr Metab Cardiovasc Dis, 2024; PMID 38172006): 43 adults with prediabetes or type 2 diabetes, 2 g/day for 14 weeks, glucose at 90 and 120 minutes of an oral glucose tolerance test lower, no change in secondary outcomes; the carnosine was provided by a manufacturer with no role in the study. Peng et al. (Complement Ther Med, 2020; PMID 31987255): meta-analysis of 4 carnosine-only trials, 184 participants, HbA1c 0.92 points lower with high heterogeneity, no effect on fasting glucose, HOMA-IR or lipids. Small, mixed: C.

PMID 29420997 PMID 38172006 PMID 31987255

Musculoskeletal measures (strength, lean mass, bone) in prediabetes or type 2 diabetes

Grade D

PMID 39770949 PMID 42308284

Why Grade C and not Grade B

Grade C reflects early or limited human evidence -- small trials, surrogate endpoints, or preliminary findings not yet independently replicated. The evidence points in a promising direction but does not yet meet the standard for Grade B. A single well-powered, independently replicated trial with a meaningful endpoint would move this to Grade B or higher.

What would move this grade

A well-powered randomized trial with an objective, clinically meaningful primary endpoint and at least one independent replication would support Grade B or higher.

How to track whether this is working The primary outcome for your specific application at baseline and 12 weeks: glycation (HbA1c, fructosamine) for metabolic use, cognitive battery for neuroprotection use, exercise performance test for athletic use. Serum carnosine is rapidly degraded by carnosinase: oral supplementation raises tissue carnosine; direct serum measurement is not a reliable proxy.